Can Bcl-2 Family Proteins be Targeted for Cancer Therapy?
Yes, targeting Bcl-2 family proteins is a promising strategy for cancer therapy. One of the most notable examples is the development of BH3 mimetics, small molecules that mimic the action of pro-apoptotic BH3-only proteins. These drugs, such as Venetoclax (ABT-199), specifically inhibit Bcl-2 and have shown significant efficacy in treating cancers like chronic lymphocytic leukemia. Other BH3 mimetics are under investigation to target different anti-apoptotic members of the Bcl-2 family.
